Johnson & Johnson Stock Price, News & Analysis

Johnson & Johnson (NYSE: JNJ) reported Week 12 results from the Phase 2b ANTHEM-UC study of icotrokinra, a once-daily oral peptide that selectively blocks the IL-23 receptor. The study met its primary endpoint with clinical response rates of 63.5% at 400 mg versus 27% for placebo (p<0.001); 200 mg and 100 mg showed 58.1% and 54.7% response rates. At Week 12 the 400 mg group achieved clinical remission 30.2% (p=0.006), symptomatic remission 46.0%, and endoscopic improvement 36.5% (p=0.002). Safety profiles and serious adverse event rates were similar to placebo through Week 12. Based on these data JNJ has initiated Phase 3 ICONIC-UC and ICONIC-CD programs and submitted an NDA in July 2025 for icotrokinra in plaque psoriasis.

Johnson & Johnson (NYSE: JNJ) announced new data (Oct 7, 2025) showing ACUVUE OASYS MAX 1-Day for ASTIGMATISM outperformed Dailies Total1 for Astigmatism on patient‑reported vision and end‑of‑day comfort.

Key results: 62% overall preference vs 18%, 65% preferred ACUVUE for digital device vision vs 16%, and a 3.3x greater preference in one study. New OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM extends daily disposable multifocal coverage to patients with 1.00–1.75 D astigmatism and is now available in the US, Canada and select EMEA/APAC markets.

Johnson & Johnson (NYSE: JNJ) will present at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, 2025. Management will appear in a Fireside Chat at 10:30 a.m. Eastern Time.

A live audio webcast will be available on Johnson & Johnson’s Investor Relations website at www.investor.jnj.com. An archived edition will be posted later the same day, and an audio webcast replay will be available approximately 48 hours after the live session.

Media and investor contact emails are provided for inquiries.

Johnson & Johnson (NYSE:JNJ) announced that the FDA has approved TREMFYA® (guselkumab) for treating children six years and older weighing at least 40 kg with moderate to severe plaque psoriasis and active psoriatic arthritis. This marks TREMFYA® as the first and only IL-23 inhibitor approved for these pediatric indications.

The approval was based on the Phase 3 PROTOSTAR study, which demonstrated significant efficacy: 56% of patients achieved PASI 90 compared to 16% on placebo, and 66% achieved high skin clearance (IGA score 0/1) versus 16% on placebo at Week 16. The treatment will be administered via subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter.

This approval addresses a significant market, targeting approximately 20,000 children under 10 diagnosed with plaque psoriasis annually and 14,000 children affected by psoriatic arthritis.

Vicarious Surgical (NYSE:RBOT) has appointed Joseph Doherty as Chairman of the Board of Directors. Doherty, who joined the board in June 2025, brings extensive healthcare and medical device industry experience, having served as CEO of Worcester City Campus Corporation and President of Scapa Healthcare.

His background includes leadership roles at Olympus Surgical Technologies America and a 24-year tenure at Johnson & Johnson, where he served as Vice President of Integration and Transformation. Doherty holds a BS in Engineering from West Point and an MBA from Nichols College.

Johnson & Johnson (NYSE: JNJ) has received FDA approval for a subcutaneous (SC) induction regimen of TREMFYA® for treating adults with moderate to severe ulcerative colitis (UC). This milestone makes TREMFYA® the first and only IL-23 inhibitor offering both SC and intravenous (IV) induction options for UC and Crohn's disease treatment.

The approval is supported by the Phase 3 ASTRO trial results, where TREMFYA® demonstrated significant improvements versus placebo: 26% vs. 7% in clinical remission and 36% vs. 12% in endoscopic improvement at Week 12. The recommended SC induction dosage is 400 mg at Weeks 0, 4, and 8, with maintenance dosing options of either 100 mg every 8 weeks or 200 mg every 4 weeks.

Additionally, JNJ is initiating a head-to-head study against Skyrizi® in Crohn's disease, highlighting confidence in TREMFYA's clinical profile.

Johnson & Johnson (NYSE:JNJ) announced promising results from its Phase 2 MajesTEC-5 study evaluating TECVAYLI® and DARZALEX FASPRO® in transplant-eligible patients with newly diagnosed multiple myeloma. The immune-based induction regimen demonstrated exceptional efficacy with 100% of evaluable patients achieving minimal residual disease (MRD) negativity following induction therapy.

Key findings include 100% overall response rate across all treatment arms, with 85.7% of patients achieving complete response or better. The treatment showed strong safety profile with manageable side effects, and 96% of patients successfully completed stem cell mobilization. No treatment discontinuations or Grade 5 adverse events were reported.

Johnson & Johnson (NYSE:JNJ) announced significant Phase 3 clinical trial results for icotrokinra, their novel targeted oral peptide for moderate-to-severe plaque psoriasis. The ICONIC-ADVANCE studies demonstrated icotrokinra's superiority over deucravacitinib in skin clearance at Weeks 16 and 24, with adverse event rates similar to placebo.

The ICONIC-LEAD study showed sustained skin clearance through Week 52, with 84% of adult PASI 90 responders maintaining response versus 21% on placebo. In adolescents, 86% achieved PASI 90 response after 52 weeks of treatment. Additionally, JNJ initiated the ICONIC-ASCEND study, the first head-to-head trial comparing an oral treatment (icotrokinra) to an injectable biologic (ustekinumab) in psoriasis treatment.

Johnson & Johnson (NYSE:JNJ) will present 21 abstracts featuring new clinical and real-world data at the 2025 Psych Congress in San Diego from September 17-21. The presentations focus on the company's neuropsychiatry portfolio, including research on major depressive disorder (MDD), treatment-resistant depression (TRD), and schizophrenia.

Key highlights include new Phase 3 data comparing seltorexant with quetiapine XR for MDD with insomnia symptoms, post-hoc analysis of CAPLYTA® in MDD patients with anxious distress, and studies evaluating SPRAVATO® as a monotherapy for TRD. The company will present posters on September 19 and 20, showcasing their commitment to advancing neuropsychiatric treatment options.